Our high-tech drug delivery system has evolved to encompass the polylactide-co-glycolide (PLGA) family of polymers. Clinical applications of controlled-release drug delivery in our technology focus on biodegradable in situ forming gel depots in which a bio therapeutic agents encapsulated in PLGA-based materials.
In order to avoid inconvenient surgical insertion of large implants, injectable biodegradable and biocompatible polymeric particles could be employed for controlled drug delivery. In situ forming semisolid depots are injected as liquids and then undergo a phase transition to a semisolid gel at the site of injection to form the drug-releasing depot. The controlled release of bioactive macromolecules via our technology has a number of advantages, such as ease of administration, more patient compliance, less complicated fabrication, and less stressful manufacturing conditions for sensitive drug molecules.